SWEET
SUPPORTING WOMEN WITH ADHERENCE TO ADJUVANT ENDOCRINE THERAPY FOLLOWING BREAST CANCER

WARWICK
CLINICAL TRIALS UNIT

SWEET Drop In

27 October 2026

Please Use QR Code to log your attendance!

https://forms.cloud.microsoft/e/TLBgNsi8x2

Topic 1: Changes to Trial Team

We have sadly said Fairwell to our Trial Co-Ordinator Anna Mann

You will continue to receive all comms as usual from Trial Manager (Raegan) and Data Entry Clerk (Matt)




You can expect to receive the following:

- Weekly Questionnaire Reminder Emails (18M Specific)
- CRF Chases both 12 and 18M (approx. every 2 weeks)
- End of Study Reminders (approx. every 4 weeks)
- Baseline Data Queries – to cover any missing or potentially illogical data- Early Nov

If you have any changes in team, please advise us- we still need updated delegation logs and training logs where applicable

Topic 2: Version Control

- We have had a significant number of questionnaires received over the last 8 weeks that have issues with version control
- Please remember you should be using v5.0 of the questionnaire
- If you cannot locate a copy in your ISF you can find this to download on the SWEET/Warwick Website
- https://warwick.ac.uk/fac/sci/med/research/ctu/trials/sweet/isf/
- Scroll Down to Section 9
- Here you can access the document and download



Topic 3: NSA24

- Sent to sites on the 08th October!
- Update to the Questionnaire Cover Letter- specific to 18M and further highlights this is the final timepoint
- 3 Site Actions Required
  - Acknowledgement of receipt
  - C&C/ Confirmation on Approval
  - Implementation Checklist
- **Fully implemented with Checklist sent back to CTU by 12th November 2026**



Topic 4: Follow Up- Schedule

- Please follow the guidance provided in the 'Follow Up Guidance' document and please action the prompt emails as soon as possible so we can optimise the full 8-week window as per the diagram below!

- sweet_follow_up_guidance_v1.0_10nov25.pdf

Time Point X, - 4 weeks
Start of Follow Up Window
You will receive an Email from SWEET ***prompting you to send the Questionnaire and complete the CRF***

Time Point X, Official Due Date
Receive an Email from SWEET **IF** we have not yet received the questionnaire, prompting the site to **follow up with the participant and encourage completion**

Time Point X, + 2 weeks
Receive an Email from SWEET **IF** we have still not yet received the questionnaire, prompting the site **to follow up with the participant and encourage completion**

Time Point X, + 4 weeks
End of Window
We will still collect and use received data but will not chase after this

Topic 4: Follow Up- Schedule

- Please consider how you may utilise the ‘traffic light system’ on the reminder emails
- We hope this well help sites to :
  - streamline communication
  - focus team capacity

- Red= Missing 6M **&** 12M Q’s
- Orange = Missing 6M **or** 12M Q’s
- Applies to both patients who are ‘now due’ and those who are pending receipt

Please find below your weekly follow up reminders.

The following participants are now in follow up window and are due their follow up questionnaire:

TNO	TimePoint (Months)	Reminder
A1	18	1
A2	18	1

Please print these and send them out with a return envelope and cover letter within the next 7 days. Please also complete the corresponding CRFs on the database.

Please can you ensure the questionnaire has the participants TNO and Initials completed and the appropriate timepoint ticked prior to sending to the participant.

Topic 4: Follow Up- How to combat participants who feel the questionnaire is no longer relevant to them

- Adding additional guidance to the website about conversations you can have with participants/ or one liners that may encourage completion of questionnaires.

- This will be available by the end of the day: Investigator Site File – Section 8 General Site information

Topic 4: Follow Up- How to combat participants who feel the questionnaire is no longer relevant to them

- Adding additional guidance to the website about conversations you can have with participants/ or one liners that may encourage completion of questionnaires.

- This will be available by the end of the day: Investigator Site File – Section 8 General Site information

- SWEET_Prompts to Aid Follow Up Completion _v1.0_27Oct2026

Value of different experiences:

- Women have different experiences when they have had breast cancer. Whatever your experience has been, even if you have stopped taking hormone therapy, it is important for us to understand it. Completing the questionnaire helps us learn what support women need in real life.

- We're really interested in understanding what happened for women during the study, whether things went smoothly or whether there were difficulties along the way. That's why hearing from everyone is so important, regardless of whether women have continued with or stopped hormone therapy

- Your questionnaire is important to ensure the study reflects the experiences of all women who took part, not just some of them. If we only get responses back from women who have continued with hormone therapy that will not give us a true picture.

Topic 4: Follow Up- How to combat participants who feel the questionnaire is no longer relevant to them

Importance of last questionnaire:

- The final questionnaire is particularly valuable because it tells us what life has been like for you over the last few months, around 18 months since you were first prescribed hormone therapy Whether you've now stopped taking it – or you are getting on fine - your answers help us understand the impact of breast cancer and its treatment on women's lives.

- The final questionnaire is especially valuable because it provides information that we can't get from the earlier questionnaires alone. It helps us understand women's experiences across the whole 18 months of the study.

- The earlier questionnaires tell us where women started, but the final questionnaire helps us understand where they are after 18 months at the end of the study. That's why this stage is particularly important.

Even if nothing has changed:

- Even if you feel nothing much has changed since your last questionnaire, that’s useful information for us to know.

Value of resource use questionnaire:

- Some of the questions ask about appointments and health services you have used. This information helps us understand what kinds of support women use and what services may be needed in the future.

- I appreciate that some of the questions about appointments, services and costs can feel repetitive. They are important because they help us understand what services women use and whether our support programme offers good value for the NHS.

Topic 4: Follow Up- How to combat participants who feel the questionnaire is no longer relevant to them

For women who have stopped HT:

- Please don't worry if you've stopped taking your hormone therapy. We are interested in understanding all women's experiences and how they have been getting on. If we only get responses back from women who have continued with hormone therapy that will not give us a true picture.

- Please don't feel that the questionnaire is only for women who are still taking hormone therapy. Decisions about treatment are personal and can be influenced by many different factors. We'd still very much value your views and experiences, whatever those have been. If we only get responses back from women who have continued with hormone therapy that will not give us a true picture.

Helping other women in the future:

- By completing the questionnaire, you're helping us understand how care and support might be improved for future patients.

- One of the aims of the study is to understand what kinds of support are most useful for women. We can only do that if participants tell us about their experiences and how they have been doing, whatever those experiences have been.

- One of the reasons we're doing this study is to improve support for future women with breast cancer. If women who have found treatment difficult, or have stopped taking hormone therapy, don't complete the questionnaires, we may miss some of the most important lessons about how support could be improved.

Making the most of your previous contribution to the study:

- You've already contributed a great deal to the study. Completing the final questionnaire means we get a full picture of what your experience has been when the study results are analysed.

Topic 5: Follow Up- 12M & 18M return rates

12M CRF's

Status	Number	%
Due	1631	n/a
Received	1629	99.9%
Missing	2	0.01%

18M CRF's

Status	Number	%
Due	869	n/a
Received	857	98.6
Missing	12	1.4%

12M Questionnaire's

Status	Number	%
Due	1618	n/a
Received	1190	73.5%
Missing	419	25.9%
Pending	9	0.6%

18M Questionnaire's

Status	Number	%
Due	857	n/a
Received	617	72%
Missing	204	23.8%
Pending	36	4.2%

Data as per the 22 October 2026

Topic 6: Other Business

- Finance
  - Please remember finance is based in NuTH- all invoices need to be sent to and addressed to nuth.projectmanagement@nhs.net.
  - 50% of all sites have been emailed (A-N), once all queries are resolved other sites will be emailed (P-Z)

- Royal Mail
  - We have been experiencing a delay in receiving post
  - We are hoping the issue has now been resolved and will start to see more post coming through over the next 2 weeks
  - If your participant has stated that they have posted their questionnaire, please make a note and let us know so we can remove them from subsequent chases.

Topic 7: Implementation Workstream

We are currently planning implementation ideals as part of the implementation work stream

- In an ideal world HT&Me would be adopted by the NHS and rolled out across services in the four nations
    - First need evidence of effectiveness and cost-effectiveness!

- We are exploring various options and routes simultaneously
    - Engaging with implementation experts and key stakeholders
    - In discussions with various organisations to“take-on ” web-app and make it available
    - Making training package for nurses/HCP available
    - Incorporation of links within other websites accessed by HCPs

Topic 8: Letter from the CI's

Sent to all on the 21st October 2026

Dear Trial Teams,

As we enter the final six months of the SWEET Trial, we would like to thank you and your team for your continued commitment and support of this important study.


Thanks to the dedication of participating sites across the UK, we have successfully recruited more than 1,600 women.

As we move towards completion, we would just like to highlight the importance of the 18-month follow-up questionnaire. These data are critical to our primary outcome analysis, and achieving the highest possible response rate will be essential to the success of the study. We would therefore be extremely grateful if you could support any local efforts to encourage questionnaire completion among participants. Every completed follow-up helps ensure that the findings are as robust and meaningful as possible.

We anticipate that trial results will be available in late 2027/ early 2028. In parallel, we are working with Cancer Alliances, the Health Innovation Network, and Charity partners to plan how the findings can be translated into practice.

Thank you again for your ongoing support and for helping us bring the SWEET Trial to a successful conclusion.

With best wishes,
Professor Linda Sharp (CI) and Professor Eila Watson (Co-CI)



Training

DISCLAIMER: The below docu


Please find below linked various SWEET site tr

TRIAL SPECIFIC TRAINING:

- Database Training Presentation
- SIV Slides (current)
  - Site Led Model
  - BCN Model

DROP IN SESSION PRESENTATIONS:

- Drop In Session 21Apr26
- Drop In Session- Data Cleaning
- Drop In Session- 10Feb26
- Drop In Session- End of Year 02Dec2025
- Drop In Session 21Oct2025



You can access all drop-in sessions on the SWEET/Warwick Website

Q & A